We performed a systematic search in PubMed and CENTRAL (Cochrane Central Register of Controlled Trials) databases, as well as in clinical registries until the 20th of August 2024, to detect all randomized control trials (RCTs) pertinent to the administration of JAK inhibitors, namely, baricitinib and upadacitinib, as well as the IL-6R inhibitor sarilumab in patients suffering from RA. This evidence concerns the gene IL6R and rheumatoid arthritis.